2025年1月1日至2025年12月31日。 2025年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 证券代码：688185 证券简称：康希诺 公告编号：2026-002 康希诺生物股份公司 （一）业绩预告期间 （二）业绩预告情况 1、经康希诺生物股份公司（以下简称"公司"）财务部门初步测算，预计2025年年度（以下简称"报告 期"）实现营业收入104,000.00万元到108,000.00万元，与上年同期相比，将增加19,366.19万元到 23,366.19万元，同比增长22.88%到27.61%。 2、预计2025年年度实现归属于母公司所有者的净利润为2,450.00万元到2,900.00万元，与上年同期相 比，将实现扭亏为盈。 3、预计2025年年度实现归属于母公司所有者扣除非经常性损益后净利润为-9,100.00万元到-9,600.00万 元。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 公司2024年年度实现营业收入为84,633.81万元，利润总额为 ...

| જેટ મેતિ | 公司 | 主要内容 | | --- | --- | --- | | 聚焦 | 臺韋点 | 筹划控制权变更事项 28日起停牌 | | | 万科A | 深铁集团向公司提供不超过23.6亿元借款 | | | 东材科技 | 实控人、副董事长熊海涛被留置 | | | 国泰海通等 | 业绩预增 | | | 多家券商 | | | | 康希诺 | 预计2025年净利润2450万元-2900万元 同比 扭亏为盈 | | | 何氏眼科 | 2025年度预盈2400万至3600万元 同比扭亏 | | | 常山北明 | 2025年度预盈3500万元 同比扭亏 | | | 国盾量子 | 预计2025年净利润500万元左右 同比扭亏为盈 | | | 宁波富邦 | 2025年净利润同比预增3099.59%-4379.43% | | | 金马游乐 | 2025年净利润同比预增811.17%-1069.56% | | | 怡球资源 | 2025年净利润同比预增620%-970% | | | 臻雷科技 | 2025年净利润同比预增530%-642% | | 业绩精选 | 英图川醋 | 2025年净利润同比预增428.3 ...

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Core Viewpoint - Several companies are expected to turn profitable by 2025, with projected net profits indicating a significant recovery from previous losses [1] Group 1: Company Projections - Saiwei Electronics is projected to achieve a net profit of 1.414 billion to 1.504 billion yuan in 2025, marking a turnaround from losses [1] - Ganfeng Lithium anticipates a net profit of 1.1 billion to 1.65 billion yuan in 2025, also indicating a return to profitability [1] - Buchang Pharma expects a net profit ranging from 320 million to 468 million yuan in 2025, reflecting a recovery [1] - Zhiguang Electric forecasts a net profit of 110 million to 160 million yuan in 2025, showing a positive shift [1] - Zhong Rare Metals predicts a net profit of 100 million to 130 million yuan in 2025, indicating a turnaround [1] - Jingwei Hengrun expects a net profit of 75 million to 110 million yuan in 2025, marking a return to profit [1] - Tongguan Copper Foil anticipates a net profit of 55 million to 75 million yuan in 2025, indicating a recovery [1] - Weijie Chuangxin projects a net profit of 45 million yuan in 2025, reflecting a positive change [1] - Changshan Beiming expects a net profit of 35 million yuan in 2025, indicating a turnaround [1] - CanSino Biologics anticipates a net profit of 24.5 million to 29 million yuan in 2025, marking a return to profitability [1] - Gaolan Co. projects a net profit of 23.5 million to 30.5 million yuan in 2025, indicating a recovery [1] - Shenkeda expects a net profit of 20 million to 29 million yuan in 2025, reflecting a positive shift [1] - Guodun Quantum anticipates a net profit of 5 million yuan in 2025, indicating a turnaround [1]

北京商报讯（记者 丁宁）1月27日晚间，康希诺（688185）发布2025年业绩预告显示，预计2025年实现 归属净利润为2450万元到2900万元，与上年同期相比，将实现扭亏为盈。 康希诺表示，报告期内，公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价 流脑结合疫苗曼海欣收入保持持续增长。同时，公司深入推进降本增效，各项费用得到有效管控；产销 协同进一步优化，毛利率亦有所提升。整体盈利能力显著提升，成功于报告期实现归属净利润为正。同 时，报告期内，随着公司研发项目的快速推进及国际合作的开展，公司获得了更多政府专项补助及国际 专项资金的支持，故于报告期产生较大金额的非经常性收益。 ...

Core Viewpoint - The company is advancing its candidate product development as planned and will share updates on progress when available [1] Group 1: R&D Progress - The company is actively progressing its candidate product research and development [1] - Updates on any significant advancements will be communicated to stakeholders [1] Group 2: Business Expansion - The company is leveraging its mRNA platform to expand related business opportunities [1] - A three-component LNP delivery system has been authorized for external use and supports other partners in research and development [1] - The company is collaborating with domestic and international partners to further enhance the application and value of its platform [1]

证券日报网讯 1月27日，康希诺在互动平台回答投资者提问时表示，公司以在世界范围内提供预防和治 疗感染类疾病的解决方案为己任，已建立了成熟的技术平台，可以针对不同病毒及细菌等的防护需要进 行疫苗的开发。公司会持续关注该事件及其发展，在评估相关事件发展情况、开发效率及投入、市场空 间及经济效益测算等因素后，如有必要会考虑后续步骤。公司会积极履行社会及国际责任，愿为全球公 共卫生事业作出贡献。 ...

（文章来源：证券日报） 证券日报网讯 1月27日，康希诺发布公告称，公司预计2025年年度实现营业收入104000.00万元到 108000.00万元，与上年同期相比，将增加19366.19万元到23366.19万元，同比增长22.88%到27.61%；预 计实现归属于母公司所有者的净利润为2450.00万元到2900.00万元，与上年同期相比，将实现扭亏为 盈。 ...

Group 1 - Heng Rui Medicine's HRS-5346 tablet has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with a total R&D investment of approximately 76.3 million yuan [2] - Yu Guang Jin Lead announced a significant stock price increase of 45.01% over five trading days, expressing uncertainty about the future price of silver [3] - Dongcai Technology's actual controller and vice chairman has been detained for investigation, but the company states that this will not significantly impact its normal operations [4] Group 2 - Aisen Co. plans to invest 2 billion yuan to establish an integrated circuit materials manufacturing base in East China, with the first phase expected to be operational by 2028 [5] - Jingpin Special Equipment has been banned from participating in procurement activities for three years, but the impact on overall operations is considered limited [6] - Nanhua Futures' overseas subsidiary has obtained membership at the Nodal Exchange, allowing it to trade and clear related products [7] Group 3 - Di'er Laser is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy [8] - Zhong Rare Earth expects a net profit of 100 million to 130 million yuan in 2025, reversing a loss from the previous year due to market improvements [10] - Shen Nan Circuit anticipates a net profit increase of 68% to 78% in 2025, driven by demand in AI computing and smart automotive sectors [11] Group 4 - Hai Xin Energy Science and Technology expects a net loss of 450 million to 640 million yuan in 2025, although this is an improvement from the previous year's loss [12] - Nan Ya New Materials forecasts a net profit increase of 337% to 417% in 2025, attributed to a recovery in the copper-clad laminate industry [13] - CanSino expects a net profit of 24.5 million to 29 million yuan in 2025, driven by the growth of its quadrivalent meningococcal vaccine [14] Group 5 - Zhi Guang Electric anticipates a net profit of 110 million to 160 million yuan in 2025, reversing a previous loss due to growth in its energy storage business [15] - Dongfang Securities expects a net profit increase of 67.8% in 2025, benefiting from capital market opportunities [17] - Jinlong Automobile forecasts a net profit increase of 193.68% in 2025, supported by growth in overseas markets [18] Group 6 - Zhen Lei Technology expects a net profit increase of 529.64% to 642.26% in 2025, driven by demand in special integrated circuits [19] - Yong Ding Co. anticipates a net profit of 200 million to 300 million yuan in 2025, reflecting significant growth from investment income [20] - Xiamen Tungsten's preliminary report indicates a net profit of 2.311 billion yuan in 2025, a 35.08% increase year-on-year [21] Group 7 - Guo Dun Quantum expects a net profit of 5 million yuan in 2025, marking a return to profitability [22] - Shi Jia Photon forecasts a net profit increase of approximately 426% in 2025, driven by growth in optical chip orders [23] - Ningbo Fubang anticipates a net profit increase of 3099.59% to 4379.43% in 2025, largely due to rising silver prices and significant non-recurring gains [24] Group 8 - Huasheng Lithium Battery plans to adjust its share repurchase price limit from 32 yuan to 150 yuan per share [26] - Aonong Biological announced plans for multiple shareholders to reduce their stakes [28] - Pizaihuang's controlling shareholder intends to increase its stake by 300 million to 500 million yuan [29]

智通财经APP讯，康希诺(688185.SH)发布2025年年度业绩预告，预计2025年年度实现归属于母公司所 有者的净利润为2,450万元到2,900万元，与上年同期相比，将实现扭亏为盈。 报告期内，公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗 曼海欣®收入保持持续增长。同时，公司深入推进降本增效，各项费用得到有效管控;产销协同进一步 优化，毛利率亦有所提升。整体盈利能力显著提升，成功于报告期实现归属于母公司所有者的净利润为 正。 ...